Soleno Therapeutics(US:SLNO) TMX Newsfile·2026-03-20 14:07Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Soleno Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements about the safety and efficacy of its drug candidate DCCR [2][4]. Group 1: Allegations and Legal Actions - The complaint alleges that Soleno and its executives made false statements and failed to disclose significant safety concerns related to the DCCR clinical trial, including issues of excess fluid retention [4]. - The company is facing a federal securities class action, with a deadline of May 5, 2026, for investors to seek the role of lead plaintiff [2][8]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [8]. Group 2: Stock Price Impact - Following a critical report by Scorpion Capital on August 15, 2025, Soleno's stock price fell from over $77 per share to approximately $68 per share, a decline of nearly 12% [5]. - After a patient death was disclosed on September 10, 2025, the stock price dropped from more than $70 per share to about $57 per share, a decline of approximately 19% [6]. - On November 4, 2025, Soleno reported financial results indicating that the earlier report disrupted the launch of DCCR, leading to a one-day stock price decline of approximately 27%, from nearly $64 to about $47 per share [7]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [3].